

Asish K Ghosh

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4734304/publications.pdf>

Version: 2024-02-01

15
papers

515
citations

1478280

6
h-index

1372474

10
g-index

15
all docs

15
docs citations

15
times ranked

978
citing authors

#	ARTICLE	IF	CITATIONS
1	Idelalisib activates AKT via increased recruitment of PI3K ¹ /PI3K ² to BCR signalosome while reducing PDK1 in post-therapy CLL cells. <i>Leukemia</i> , 2022, 36, 1806-1817.	3.3	2
2	SIRT3 overexpression and epigenetic silencing of catalase regulate ROS accumulation in CLL cells activating AXL signaling axis. <i>Blood Cancer Journal</i> , 2021, 11, 93.	2.8	9
3	HSP90 overexpression potentiates the B-cell receptor and fibroblast growth factor receptor survival signals in chronic lymphocytic leukemia cells. <i>Oncotarget</i> , 2020, 11, 2037-2046.	0.8	2
4	Targeted Axl Inhibition Primes Chronic Lymphocytic Leukemia B Cells to Apoptosis and Shows Synergistic/Additive Effects in Combination with BTK Inhibitors. <i>Clinical Cancer Research</i> , 2015, 21, 2115-2126.	3.2	59
5	Critical Signal Transduction Pathways in CLL. <i>Advances in Experimental Medicine and Biology</i> , 2013, 792, 215-239.	0.8	9
6	Novel Pharmacological Agents Differentially Modulate Cytokine Release On CLL B-Cell-Stromal Cell Co-Culture: Implications for Stromal Rescue of CLL B-Cells From Chemotherapy. <i>Blood</i> , 2012, 120, 3927-3927.	0.6	0
7	The novel receptor tyrosine kinase Axl is constitutively active in B-cell chronic lymphocytic leukemia and acts as a docking site of nonreceptor kinases: implications for therapy. <i>Blood</i> , 2011, 117, 1928-1937.	0.6	109
8	Axl Receptor Tyrosine Kinase Signaling Pathway and the p53 Tumor Suppressor Protein Exist In A Novel Regulatory Loop In B-Cell Chronic Lymphocytic Leukemia Cells. <i>Blood</i> , 2011, 118, 799-799.	0.6	1
9	TRIS (DIBENZYLIDENEACETONE) Dipalladium a Small-Molecule Palladium Complex Is Effective in the Induction of Apoptosis for B-Chronic Lymphocytic Leukemia B-Cells. <i>Blood</i> , 2011, 118, 2851-2851.	0.6	1
10	Epigallocatechin-3-Gallate (EGCG) Modulates Cytokine Production When Leukemic CLL B-Cells and Marrow Stromal Cells Are Co-Cultured: Correlations with Clinical Activity in a Phase II Trial,. <i>Blood</i> , 2011, 118, 3882-3882.	0.6	0
11	Circulating microvesicles in B-cell chronic lymphocytic leukemia can stimulate marrow stromal cells: implications for disease progression. <i>Blood</i> , 2010, 115, 1755-1764.	0.6	208
12	Curcumin Inhibits Prosurvival Pathways in Chronic Lymphocytic Leukemia B Cells and May Overcome Their Stromal Protection in Combination with EGCG. <i>Clinical Cancer Research</i> , 2009, 15, 1250-1258.	3.2	114
13	Crosstalk between Chronic Lymphocytic Leukemia (CLL) B-Cells and Marrow Stromal Cells: Implication for CLL B-Cell Activation and Survival.. <i>Blood</i> , 2007, 110, 337-337.	0.6	1
14	Dietary Products Induce Apoptosis in CLL B Cells and Reveal Potential as a Therapeutic Combination That Can Overcome Stromal Cell Mediated Protection.. <i>Blood</i> , 2007, 110, 3130-3130.	0.6	0
15	Characterization of Microvesicles in B-Cell Chronic Lymphocytic Leukemia (CLL): A Potential Mediator in CLL B Cell Disease Progression?.. <i>Blood</i> , 2007, 110, 747-747.	0.6	0